scispace - formally typeset
Search or ask a question
Institution

Mayo Clinic

HealthcareRochester, Minnesota, United States
About: Mayo Clinic is a healthcare organization based out in Rochester, Minnesota, United States. It is known for research contribution in the topics: Population & Transplantation. The organization has 63387 authors who have published 169578 publications receiving 8114006 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: There is increasing evidence that a combination of currently existing neuroimaging and cerebrospinal fluid (CSF) and blood biomarkers can provide important complementary information and thus contribute to a more accurate and earlier diagnosis of AD.
Abstract: With the increasing life expectancy in developed countries, the incidence of Alzheimer’s disease (AD) and thus its socioeconomic impact are growing. Increasing knowledge over the last years about the pathomechanisms involved in AD allow for the development of specific treatment strategies aimed at slowing down or even preventing neuronal death in AD. However, this requires also that (1) AD can be diagnosed with high accuracy, because non-AD dementias would not benefit from an AD-specific treatment; (2) AD can be diagnosed in very early stages when any intervention would be most effective; and (3) treatment efficacy can be reliably and meaningfully monitored. Although there currently is no ideal biomarker that would fulfill all these requirements, there is increasing evidence that a combination of currently existing neuroimaging and cerebrospinal fluid (CSF) and blood biomarkers can provide important complementary information and thus contribute to a more accurate and earlier diagnosis of AD. The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is exploring which combinations of these biomarkers are the most powerful for diagnosis of AD and monitoring of treatment effects.

992 citations

Journal ArticleDOI
TL;DR: Coronary calcium quantification is an excellent method of assessing atherosclerotic plaque presence at individual artery sites and the remodeling phenomenon is the likely explanation for the lack of a good predictive value between lumen narrowing and quantification of mural calcification.

991 citations

Journal ArticleDOI
01 Jan 2009-Leukemia
TL;DR: A new risk stratification model is provided to specifically define high-risk patients who may benefit from novel therapeutic strategies in multiple myeloma.
Abstract: New systems have emerged for diagnosis, staging and response assessment in multiple myeloma (MM). The diagnostic and response criteria recommended are primarily derived from the International Myeloma Working Group, with certain updates and clarifications. The International Staging System is the current standard for staging of myeloma. A new risk stratification model is provided to specifically define high-risk patients who may benefit from novel therapeutic strategies. This paper provides the current criteria for diagnosis, staging, risk stratification and response assessment of MM.

991 citations

Journal ArticleDOI
Stephan Ripke1, Naomi R. Wray2, Cathryn M. Lewis3, Steven P. Hamilton4, Myrna M. Weissman5, Gerome Breen3, Enda M. Byrne2, Douglas Blackwood6, Dorret I. Boomsma7, Sven Cichon8, Andrew C. Heath9, Florian Holsboer, Susanne Lucae4, Pamela A. F. Madden9, Nicholas G. Martin2, Peter McGuffin3, Pierandrea Muglia8, Markus M. Noethen10, Brenda P Penninx7, Michele L. Pergadia9, James B. Potash11, Marcella Rietschel10, Danyu Lin12, Bertram Müller-Myhsok8, Jianxin Shi13, Stacy Steinberg8, Hans J. Grabe, Paul Lichtenstein14, Patrik K. E. Magnusson14, Roy H. Perlis7, Martin Preisig15, Jordan W. Smoller16, Kari Stefansson, Rudolf Uher3, Zoltán Kutalik17, Katherine E. Tansey3, Alexander Teumer, Alexander Viktorin14, Michael R. Barnes11, Thomas Bettecken18, Elisabeth B. Binder19, René Breuer10, Victor M. Castro20, Susanne Churchill13, William Coryell11, Nicholas John Craddock, Ian W. Craig3, Darina Czamara6, Eco J. C. de Geus7, Franziska Degenhardt8, Anne Farmer3, Maurizio Fava16, Josef Frank10, Vivian S. Gainer, Patience J. Gallagher16, Scott D. Gordon2, Sergey Goryachev, Magdalena Gross8, Michel Guipponi21, Anjali K. Henders2, Stefan Herms8, Ian B. Hickie22, Susanne Hoefels8, Witte J.G. Hoogendijk3, Jouke-Jan Hottenga7, Dan V. Iosifescu16, Marcus Ising9, Ian Jones2, Lisa Jones22, Tzeng Jung-Ying15, James A. Knowles18, Isaac S. Kohane16, Martin A. Kohli2, Ania Korszun9, Mikael Landén5, William Lawson19, Glyn Lewis23, Donald J. MacIntyre6, Wolfgang Maier8, Manuel Mattheisen8, Patrick J. McGrath5, Andrew M. McIntosh6, Alan W. McLean6, Christel M. Middeldorp7, Lefkos T. Middleton23, G. M. Montgomery2, Shawn N. Murphy16, Matthias Nauck, Willem A. Nolen, Dale R. Nyholt2, Michael Conlon O'Donovan24, Hogni Oskarsson, Nancy L. Pedersen14, William A. Scheftner20, Andrea Schulz, Thomas G Schulze16, Stanley I. Shyn9, Engilbert Sigurdsson, Susan L. Slager25, Johannes H. Smit7, Hreinn Stefansson17, Michael Steffens8, Thorgeir E. Thorgeirsson, Federica Tozzi, Jens Treutlein10, Manfred Uhr, Edwin J. C. G. van den Oord26, Gerard van Grootheest7, Henry Völzke14, Jeffrey B. Weilburg16, Gonneke Willemsen7, Frans G. Zitman27, Benjamin M. Neale, Mark J. Daly1, Douglas F. Levinson28, Patrick F. Sullivan12 
TL;DR: This article conducted a genome-wide association studies (GWAS) mega-analysis for major depressive disorder (MDD) using more than 1.2 million autosomal and X chromosome single-nucleotide polymorphisms (SNPs) in 18,759 independent and unrelated subjects of recent European ancestry.
Abstract: Prior genome-wide association studies (GWAS) of major depressive disorder (MDD) have met with limited success. We sought to increase statistical power to detect disease loci by conducting a GWAS mega-analysis for MDD. In the MDD discovery phase, we analyzed more than 1.2 million autosomal and X chromosome single-nucleotide polymorphisms (SNPs) in 18 759 independent and unrelated subjects of recent European ancestry (9240 MDD cases and 9519 controls). In the MDD replication phase, we evaluated 554 SNPs in independent samples (6783 MDD cases and 50 695 controls). We also conducted a cross-disorder meta-analysis using 819 autosomal SNPs with P<0.0001 for either MDD or the Psychiatric GWAS Consortium bipolar disorder (BIP) mega-analysis (9238 MDD cases/8039 controls and 6998 BIP cases/7775 controls). No SNPs achieved genome-wide significance in the MDD discovery phase, the MDD replication phase or in pre-planned secondary analyses (by sex, recurrent MDD, recurrent early-onset MDD, age of onset, pre-pubertal onset MDD or typical-like MDD from a latent class analyses of the MDD criteria). In the MDD-bipolar cross-disorder analysis, 15 SNPs exceeded genome-wide significance (P<5 × 10(-8)), and all were in a 248 kb interval of high LD on 3p21.1 (chr3:52 425 083-53 822 102, minimum P=5.9 × 10(-9) at rs2535629). Although this is the largest genome-wide analysis of MDD yet conducted, its high prevalence means that the sample is still underpowered to detect genetic effects typical for complex traits. Therefore, we were unable to identify robust and replicable findings. We discuss what this means for genetic research for MDD. The 3p21.1 MDD-BIP finding should be interpreted with caution as the most significant SNP did not replicate in MDD samples, and genotyping in independent samples will be needed to resolve its status.

989 citations

Journal ArticleDOI
19 Oct 2017-Blood
TL;DR: SCHOLAR-1, an international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively evaluated outcomes in patients with refractory DLBCL, the largest patient-level pooled retrospective analysis to characterize response rates and survival for a population of patients withRefractoryDLBCL.

987 citations


Authors

Showing all 64325 results

NameH-indexPapersCitations
Eugene Braunwald2301711264576
Peter Libby211932182724
Cyrus Cooper2041869206782
Rob Knight2011061253207
Robert M. Califf1961561167961
Eric J. Topol1931373151025
Dennis W. Dickson1911243148488
Gordon B. Mills1871273186451
Julie E. Buring186950132967
Patrick W. Serruys1862427173210
Cornelia M. van Duijn1831030146009
Paul G. Richardson1831533155912
John C. Morris1831441168413
Valentin Fuster1791462185164
Ronald C. Petersen1781091153067
Network Information
Related Institutions (5)
Brigham and Women's Hospital
110.5K papers, 6.8M citations

98% related

Cleveland Clinic
79.3K papers, 3.4M citations

98% related

Icahn School of Medicine at Mount Sinai
76K papers, 3.7M citations

97% related

Johns Hopkins University School of Medicine
79.2K papers, 4.7M citations

96% related

University of Alabama at Birmingham
86.7K papers, 3.9M citations

96% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
2023268
20221,216
202112,779
202011,352
201910,004
20188,870